Sana Biotechnology: Scope Goes Beyond HIP-Modified Pancreatic Islet Cells For T1D [Seeking Alpha]
Sana Biotechnology, Inc. (SANA)
Company Research
Source: Seeking Alpha
Sana Biotechnology's HIP-modified islet cell therapy showed a 6-month insulin response without needing immunosuppression in one T1D patient, supporting a paradigm shift in treatment. Upcoming 2025 data readouts from phase 1 GLEAM (SC291, autoimmune disorders) and VIVID (SC262, B-cell malignancies) trials are key catalysts for Sana Biotechnology. The financial runway extends into H2 2026, but Sana Biotechnology investors should monitor dilution risk as additional capital raises may follow positive clinical milestones. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » jittawit.21/iStock via Getty Images The last time I wrote an article on Sana Biotechnology, Inc. NASDAQ: SANA ), it was in a Seeking Alpha article entitled "Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment." With respect More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech An
Show less
Read more
Impact Snapshot
Event Time:
SANA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SANA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SANA alerts
High impacting Sana Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
SANA
News
- Sana Biotechnology (SANA): Assessing Valuation After Strong Year-to-Date Share Price Gains [Yahoo! Finance]Yahoo! Finance
- Sana Biotechnology to Present at December 2025 Investor ConferencesGlobeNewswire
- Sana Biotechnology (NASDAQ:SANA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SANA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Sana Biotechnology (SANA) Wins Analyst Support With Strategic Focus and Cash Strength [Yahoo! Finance]Yahoo! Finance
- Can Sana Biotechnology's (SANA) Leaner Cost Structure Strengthen Its Long-Term Competitive Position? [Yahoo! Finance]Yahoo! Finance
SANA
Earnings
- 8/11/25 - Beat
SANA
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- SANA's page on the SEC website